Estonian SNP Startup Asper Clears Licensing Hurdle to Selling Arrays in US Market | GenomeWeb

Estonian startup Asper Biotech has cleared the way to market its microarray-based Genorama genotyping system in the US, through securing a license to the SNP-IT primer extension technology from Orchid Biosciences of Princeton, NJ.

Asper, which is based in Estonia’s academic capital of Tartu, paid Orchid a one-time license fee in addition to yielding somewhere around 10 percent of royalties for the genotyping technology, said Orchid’s communications vice president Barbara Lindheim.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.